These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 11977539)

  • 1. [CGS 20267 (Letrozole), a new aromatase inhibitor: early phase II study for postmenopausal women with advanced breast cancer].
    Nomura Y; Tominaga T; Enomoto K; Aoyama H; Nakamura Y; Abe R; Sano M; Nomizu T; Tohge T; Takashima S; Ohashi Y
    Gan To Kagaku Ryoho; 2002 Apr; 29(4):551-62. PubMed ID: 11977539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Double-blind randomised trial comparing the non-steroidal aromatase inhibitors letrozole and fadrozole in postmenopausal women with advanced breast cancer.
    Tominaga T; Adachi I; Sasaki Y; Tabei T; Ikeda T; Takatsuka Y; Toi M; Suwa T; Ohashi Y
    Ann Oncol; 2003 Jan; 14(1):62-70. PubMed ID: 12488294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [CGS20267 (Letrozole), a new aromatase inhibitor: late phase II study in postmenopausal women with advanced or recurrent breast cancer (no. 2)--evaluation of efficacy and safety at the recommended clinical dose CGS20267 Study Group].
    Kimijima I; Tominaga T; Nomizu T; Nomura Y; Takashima S; Koyama H; Sano M; Tohge T; Ueo H; Ikeda S; Ohashi Y;
    Gan To Kagaku Ryoho; 2002 May; 29(5):741-9. PubMed ID: 12040678
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [CGS20267 (Letrozole), a new aromatase inhibitor: late phase II study for postmenopausal women with advanced or recurrent breast cancer (no. 1)--investigation of recommended clinical dose CGS20267 Study Group].
    Abe R; Tominaga T; Nomizu T; Nomura Y; Takashima S; Koyama H; Sano M; Tohge T; Ueo H; Ikeda S; Ohashi Y;
    Gan To Kagaku Ryoho; 2002 May; 29(5):729-40. PubMed ID: 12040677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate.
    Buzdar A; Douma J; Davidson N; Elledge R; Morgan M; Smith R; Porter L; Nabholtz J; Xiang X; Brady C
    J Clin Oncol; 2001 Jul; 19(14):3357-66. PubMed ID: 11454883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Introduction of new drug: letrozole, a new non-steroidal aromatase inhibitor for the treatment of postmenopausal women with breast cancer].
    Tsukagoshi S
    Gan To Kagaku Ryoho; 2006 Jun; 33(6):859-63. PubMed ID: 16770112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer in Korea.
    Beom SH; Oh J; Kim TY; Lee KH; Yang Y; Suh KJ; Moon HG; Han SW; Oh DY; Han W; Kim TY; Noh DY; Im SA
    Cancer Res Treat; 2017 Apr; 49(2):454-463. PubMed ID: 27554482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study.
    Eiermann W; Paepke S; Appfelstaedt J; Llombart-Cussac A; Eremin J; Vinholes J; Mauriac L; Ellis M; Lassus M; Chaudri-Ross HA; Dugan M; Borgs M;
    Ann Oncol; 2001 Nov; 12(11):1527-32. PubMed ID: 11822750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Letrozole. A review of its use in postmenopausal women with advanced breast cancer.
    Lamb HM; Adkins JC
    Drugs; 1998 Dec; 56(6):1125-40. PubMed ID: 9878997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Letrozole: a review of its use in postmenopausal women with breast cancer.
    Simpson D; Curran MP; Perry CM
    Drugs; 2004; 64(11):1213-30. PubMed ID: 15161328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.
    ; Thürlimann B; Keshaviah A; Coates AS; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Rabaglio M; Smith I; Wardley A; Price KN; Goldhirsch A
    N Engl J Med; 2005 Dec; 353(26):2747-57. PubMed ID: 16382061
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Letrozole (CGS 20267), a new oral aromatase inhibitor for the treatment of advanced breast cancer in postmenopausal patients.
    Trunet PF; Bhatnagar AS; Chaudri HA; Hornberger U
    Acta Oncol; 1996; 35 Suppl 5():15-8. PubMed ID: 9142959
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Letrozole (Femara), a new aromatase inhibitor for advanced breast cancer].
    Gershanovich M; Chaudri Kh; Campos D; Lurie H; Bonaventura A; Jeffrey M; Buzzi F; Bodrogi I; Ludwig H; Reichard P; O'Higgins NO; Romieu G; Friedrich P; Lassus M
    Vopr Onkol; 1999; 45(4):361-8. PubMed ID: 10532092
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer. Letrozole International Trial Group (AR/BC3).
    Gershanovich M; Chaudri HA; Campos D; Lurie H; Bonaventura A; Jeffrey M; Buzzi F; Bodrogi I; Ludwig H; Reichardt P; O'Higgins N; Romieu G; Friederich P; Lassus M
    Ann Oncol; 1998 Jun; 9(6):639-45. PubMed ID: 9681078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Arimidex Study Group.
    Buzdar AU; Jones SE; Vogel CL; Wolter J; Plourde P; Webster A
    Cancer; 1997 Feb; 79(4):730-9. PubMed ID: 9024711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial.
    Ingle JN; Tu D; Pater JL; Martino S; Robert NJ; Muss HB; Piccart MJ; Castiglione M; Shepherd LE; Pritchard KI; Livingston RB; Davidson NE; Norton L; Perez EA; Abrams JS; Cameron DA; Palmer MJ; Goss PE
    Breast Cancer Res Treat; 2006 Oct; 99(3):295-300. PubMed ID: 16541302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of first-line letrozole versus tamoxifen as a function of age in postmenopausal women with advanced breast cancer.
    Mouridsen H; Chaudri-Ross HA
    Oncologist; 2004; 9(5):497-506. PubMed ID: 15477634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
    Coates AS; Keshaviah A; Thürlimann B; Mouridsen H; Mauriac L; Forbes JF; Paridaens R; Castiglione-Gertsch M; Gelber RD; Colleoni M; Láng I; Del Mastro L; Smith I; Chirgwin J; Nogaret JM; Pienkowski T; Wardley A; Jakobsen EH; Price KN; Goldhirsch A
    J Clin Oncol; 2007 Feb; 25(5):486-92. PubMed ID: 17200148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate.
    Dombernowsky P; Smith I; Falkson G; Leonard R; Panasci L; Bellmunt J; Bezwoda W; Gardin G; Gudgeon A; Morgan M; Fornasiero A; Hoffmann W; Michel J; Hatschek T; Tjabbes T; Chaudri HA; Hornberger U; Trunet PF
    J Clin Oncol; 1998 Feb; 16(2):453-61. PubMed ID: 9469328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Late phase II study of exemestane in postmenopausal patients with breast cancer resistant to anti-estrogenic agents].
    Watanabe T; Sano M; Toi M; Saeki T; Kanda K; Miura S; Inaji H; Sono H; Saeki H; Nishimura R; Fujita Y
    Gan To Kagaku Ryoho; 2002 Jul; 29(7):1211-21. PubMed ID: 12146002
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.